Rilimogene galvacirepvec: Phase II started

Bavarian Nordic said investigators began an open-label, U.S. Phase II trial to evaluate subcutaneous ProstVac and IV Yervoy ipilimumab each as monotherapy or in combination in 75 patients undergoing r...